Extract to table

NOW, THEREFORE, in consideration of the mutual covenants, representations, warranties, and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: ARTICLE 1 — DEFINITIONS As used in this Agreement, the following terms shall have the meanings set forth below

Capitalized terms used but not defined in any particular provision of this Agreement shall have the meanings ascribed to them elsewhere in this Agreement or in the Exhibits and Schedules attached hereto

15 "Effective Date" means the date first written above in the preamble to this Agreement, which shall be the date on which all Conditions Precedent have been satisfied in accordance with Article 4

19 "Individual Site Agreement" means the joinder agreement, substantially in the form attached hereto as Exhibit C, to be executed by each Participating Site as a condition to that Participating Site's participation in the Study, pursuant to which such Participating Site agrees to be bound by the applicable terms and conditions of this Agreement

21 "Investigator" means, with respect to each Participating Site, the principal investigator, co-principal investigators, and sub-investigators designated by Site Network and approved by Sponsor to conduct the Study at such Participating Site, each of whom shall have executed an FDA Form 1572 and an Investigator Undertaking in the form attached hereto as Exhibit I

(b) The following institutions shall serve as the lead sites for the Study: (i) Graystone University Medical Center (Site 001), located at 1200 University Avenue, Philadelphia, Pennsylvania 19104, which shall serve as the primary lead site and the institution of the Global Principal Investigator; and (ii) Lakemont Medical Center (Site 002), located at 4400 North Michigan Drive, Chicago, Illinois 60611, which shall serve as the secondary lead site and the institution of the Co-Principal Investigator